Navigation Links
Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh
Date:2/5/2010

SINGAPORE, UPPSALA, Sweden and CANTON, Mass., Feb. 5 /PRNewswire/ -- Novus Scientific Pte. Ltd today announced that the US Food and Drug Administration (FDA) has given the company 510(k) clearance to market the TIGR™ Matrix Surgical Mesh, for use in reinforcement of soft tissues where weakness exists. TIGR™ Matrix Surgical Mesh is a 100 percent resorbable, synthetic matrix, knitted from two different resorbable fibers that degrade at different rates following implantation. This unique patented dual-fibre design provides an initial high strength / high stability configuration, with gradually increasing compliance over time as the product is resorbed.  The macroporous structure is designed to allow tissue integration for reliable tissue repair.

TIGR™ Matrix Surgical Mesh is the world's first long-term resorbable, synthetic matrix, with dual stage mechanics, which is a significant new addition to the surgeon's toolbox.

"This technology is a new treatment option, which fills a gap in the market for ventral, incisional and inguinal hernia patients, and may avoid the potential long-term complications of permanent synthetic meshes," said Bruce Ramshaw, MD.

"It is very desirable to avoid leaving permanent foreign materials in the body. This provides us with a new tool to repair abdominal wall defects in a very logical way," said A/Prof. Stellan Bjorck of Sahlgrenska University Hospital, Gothenburg, Sweden.  A/Prof. Bjorck is the Principle Investigator for the first clinical study of the TIGR™ Matrix Surgical Mesh that recently completed enrollment.

"This new technology is exciting as it represents a breakthrough in hernia mesh repair -- TIGR™ Matrix Surgical Mesh is a new synthetic mesh that is 100% resorbable. From early clinical experience, it may provide a new therapeutic option for inguinal hernia and in the future for ventral and incisional hernia repair," said A/Prof. Davide Lomanto, President of the Asia-Pacific Hernia Society and Senior Consultant at National University Hospital, Singapore.

"We are very excited to be able to introduce the TIGR™ Matrix Surgical Mesh to US surgeons, as the first in a line of state-of-the-art synthetic resorbable medical devices," said Thomas Engstrom, CEO & President of Novus.

About Novus Scientific

Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices.  Global HQ is in Singapore while European HQ and the core R&D function are in Uppsala, Sweden.   The company's roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). Novus also has offices in the US and UK.

TIGR™ is a trademark of Novus Scientific Pte. Ltd.

CONTACT:  Ben Craven, +46-730-345522, ben.craven@novusscientific.com, or James Archetto, +1-781-577-2599, jim.archetto@novusscientific.com, both of Novus Scientific Pte. Ltd

SOURCE Novus Scientific Pte. Ltd

RELATED LINKS
http://www.novusscientific.com

'/>"/>

SOURCE Novus Scientific Pte. Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Microfluidics Enters into Exclusive Partnership with ATS Scientific to Expand Distribution in Canada
2. Derycz Scientific Featured In DDN (Drug Discovery News)
3. Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
4. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
5. Professor Riccardo Lencioni Joins Delcath Systems Scientific Advisory Board
6. International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia
7. Boston Scientific Announces Election of Nelda Connors to Its Board of Directors
8. Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health
9. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
10. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
11. Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):